A polypeptide for inhibiting the replication of porcine epidemic diarrhea virus and its application.
By designing a transmembrane peptide R58A that targets arginine at position 58 of the PEDV nucleocapsid N protein, the problem of inhibiting PEDV replication in existing technologies has been solved, achieving a significant viral inhibition effect and providing new ideas for the development of antiviral drugs and vaccines.
Patent Information
- Application Number
- CN202411440181.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-15
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2044-10-15
AI Technical Summary
The lack of effective methods in the current technology to target and inhibit the replication of porcine epidemic diarrhea virus (PEDV) has resulted in poor vaccine efficacy and the lack of specificity of therapeutic drugs such as interferon and egg yolk antibodies, making it difficult to effectively suppress the spread of the virus.
A transmembrane peptide R58A targeting the PEDV replication phase was designed. Using arginine at position 58 of the PEDV nucleocapsid N protein as the target, a 20-amino acid peptide was synthesized by mutating it to alanine and adding transmembrane peptide modification to inhibit viral replication.
It significantly inhibits PEDV replication and reduces viral N and S1 protein expression, providing a new prevention and control approach. It is suitable for the preparation of antiviral drugs and vaccines and has the potential to fight coronaviruses with a broad spectrum.
Smart Images

Figure CN119119304B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of bioengineering technology, specifically relating to a polypeptide for inhibiting the replication of porcine epidemic diarrhea virus and its applications. Background Technology
[0002] Porcine epidemic diarrhea virus (PEDV) has caused widespread outbreaks of porcine epidemic diarrhea globally in recent years, resulting in an acute, highly contagious intestinal disease that causes fatal watery diarrhea in newborn piglets. Due to the significant public health threat and economic burden it poses to the pig industry, it has become one of the most significant pathogens threatening pig farming. Therefore, clarifying the infection control, immune evasion, and pathogenic mechanisms of this virus is of great importance for its prevention and control.
[0003] PEDV belongs to the genus Acoronavirus in the family Coronaviridae. It is a single-stranded positive-sense RNA virus enclosed in an envelope. Its genome is about 28kb in length and encodes four structural proteins: spike (S) protein, envelope (E) protein, membrane (M) protein, and nucleocapsid (N) protein, one accessory protein (ORF3), and 16 non-structural proteins (Nsp 1-16).
[0004] Regarding the control of PEDV, as an RNA virus, it is highly prone to mutation, undergoing complex and rapid evolution and recombination, resulting in a continued high mortality rate in vaccinated pig herds since 2010. Currently, over 98% of circulating strains belong to the G2 group, and there is still no sufficiently safe and effective vaccine against G2 PEDV. Once an outbreak occurs in a pig farm, the importance of treatment drugs becomes increasingly apparent. Clinically, treatment typically involves the administration of interferon and passive immunization with PEDV-specific egg yolk antibodies. Interferon is a general drug for treating viral diseases, but it lacks specificity and has limited therapeutic effects. Egg yolk antibodies, on the other hand, have problems such as limited protection period and inconsistent quality. Neither directly targets the PEDV virus, making it difficult to achieve good inhibitory effects against the PEDV virus in practical applications.
[0005] Therefore, it is necessary to adjust the new approach to suppressing the spread of PEDV virus and propose new solutions. Summary of the Invention
[0006] The technical problem to be solved by the present invention is to overcome the shortcomings of the prior art and provide a polypeptide for inhibiting the replication of porcine epidemic diarrhea virus and its application.
[0007] To solve the technical problem, the solution of the present invention is:
[0008] A polypeptide for inhibiting the replication of porcine epidemic diarrhea virus is provided. This polypeptide is a membrane-penetrating polypeptide that targets the replication phase of PEDV, with arginine at position 58 in the nucleocapsid N protein sequence of PEDV as the target site. The polypeptide is named R58A polypeptide, and its amino acid sequence is shown in SEQ ID NO:1.
[0009] As a preferred embodiment of the present invention, the N-terminus of the polypeptide is modified with a membrane-penetrating peptide, wherein the membrane-penetrating peptide is a CCP, and its sequence is shown in SEQ ID NO:2.
[0010] The present invention further provides a method for inhibiting PEDV virus replication using the aforementioned polypeptide, which involves pre-incubating IPEC-J2, Vero, or ST cells with the polypeptide, adding the same amount of polypeptide as during pre-incubation after PEDV infection, lysing the cells and harvesting the sample, and detecting the expression of PEDV-N protein in the cells.
[0011] As a preferred embodiment of the present invention, the concentration of the polypeptide used during polypeptide pre-incubation is 1 to 10 μg / mL.
[0012] The present invention also provides a pharmaceutical composition for inhibiting the replication of porcine epidemic diarrhea virus, said pharmaceutical composition comprising the aforementioned polypeptide, and a pharmaceutically acceptable carrier or adjuvant.
[0013] The present invention further provides the use of the polypeptide composition in the preparation of vaccines or medicaments for the prevention and / or treatment of porcine epidemic diarrhea virus.
[0014] Description of the invention principle:
[0015] Given that the practical application of existing research results on PEDV prevention is not ideal, this invention proposes a novel solution: to design a polypeptide that inhibits PEDV replication, thereby interrupting the spread of PEDV.
[0016] During the research, the applicant noted that the nucleocapsid (N) protein in the PEDV structural proteins is highly conserved and forms a complex with genomic RNA, affecting viral RNA synthesis, packaging, and viral particle assembly. The PEDV N protein also prolongs the cellular DNA synthesis phase (S phase), induces endoplasmic reticulum stress, and inhibits type III IFN production. The N-terminal domain (NTD) of the PEDV N protein mediates RNA binding and is a key domain affecting N protein function. Furthermore, the arginine contained in the N protein is a basic amino acid involved in various biological processes and can provide a crucial nutrient required during viral infection.
[0017] Based on the aforementioned research findings on the properties of the N protein and arginine, the applicant's research team clarified the infection regulation mechanism of PEDV and innovatively proposed using arginine, a specific target site in the PEDV N protein, as a modification target, thus providing a new approach to solutions. In existing research, there is no clear record of utilizing the properties of nucleocapsid (N) proteins and arginine to interrupt the PEDV replication process and thereby inhibit viral spread.
[0018] The applicant conducted in-depth research and complex screening of arginine residues in the N-terminal domain (NTD) of the PEDV N protein, ultimately confirming that arginine residue position 58 (N-R58) of the nucleocapsid protein determines the replication ability of PEDV. Based on this, the applicant further proposed the following peptide design scheme:
[0019] (1) Based on the N-terminal sequence characteristics of the PEDV N protein, 20 amino acids, including the arginine site, are extracted. Since the purity, reactivity, and ease of synthesis of a polypeptide are related to the number of amino acids, about 30 amino acids are generally preferred. Therefore, except for the transmembrane peptide containing 11 amino acids, the target polypeptide proposed in this application has a length of 20 amino acids.
[0020] (2) After determining the amino acid sequence of the polypeptide, the central arginine was mutated to alanine, and a transmembrane peptide sequence was inserted at the N-terminus to assist the polypeptide in entering the cell, and finally the polypeptide (named R58A) was synthesized. The purpose of mutating the central arginine to alanine is to disable the function of this site.
[0021] Validation in a natural PEDV infection model showed that the R58A peptide obtained in this application can significantly inhibit PEDV replication.
[0022] Compared with the prior art, the beneficial effects of the present invention are:
[0023] 1. This invention identifies key sites affecting viral replication in the N-terminal region of the PEDV N protein through in-depth research. Utilizing the highly conserved nature of these sites among different coronaviruses, it proposes them as new targets for broad-spectrum anti-coronavirus drugs and attenuated coronavirus vaccines.
[0024] 2. The present invention further provides a transmembrane peptide targeting the replication stage of PEDV based on a new target. This peptide showed a significant inhibitory effect in the PEDV infection model verification experiments of IPEC-J2, Vero, and ST cells, and can be further used as an active component to prepare anti-porcine epidemic diarrhea drugs.
[0025] 3. This invention clarifies that the conserved arginine residue at the N-terminus of the PEDV nucleocapsid protein is a key site affecting PEDV infection. Based on this, a transmembrane peptide targeting this site can be designed to exert antiviral function. This invention further enriches the research strategies for the regulation and pathogenesis of PEDV infection, providing new ideas for developing novel prevention and control methods.
[0026] 4. This invention can also provide researchers with new insights into the regulatory patterns of viral infection and the search for new clues for prevention and control in their research on other similar coronaviruses. Attached Figure Description
[0027] Figure 1 This is a description of the structure of the R58A polypeptide in this invention.
[0028] Figure 2 This is the identification result of the R58A polypeptide in this invention.
[0029] Figure 3 To analyze the cytotoxicity of different concentrations of R58A peptide to IPEC-J2 cells.
[0030] Figure 4 Analysis of the effect of R58A peptide on PEDV replication.
[0031] Figure 5 Analysis of the role of R58A peptide in PEDV infection of other susceptible cells. Detailed Implementation
[0032] The technical solutions provided by the present invention will be described in detail below with reference to the embodiments. However, they should not be construed as limiting the scope of protection of the present invention. The present invention is not limited to the following embodiments. The test methods not described in detail in the embodiments are all conventional methods in the art.
[0033] Example 1: R58A peptide inhibits PEDV replication
[0034] (1) Targeting the synthesis of peptides from PEDV N protein R58
[0035] The PEDV N protein sequence (GenBank: MK409659.1) was downloaded from the NCBI database. Arginine at position 58 (N-R58) of this nucleocapsid protein can affect PEDV replication. Based on the description in the invention principle section, the amino acids before and after arginine were designed. Then, arginine at this site was mutated to alanine, and cell-penetrating peptides (CPPs) were added, ultimately forming the R58A polypeptide. The specific sequence of this polypeptide is shown in Table 1. The underlined abbreviation A in this sequence represents alanine, which is derived from arginine.
[0036] The synthesis of the polypeptide product was outsourced to Shanghai Hongtai Biotechnology Co., Ltd. The polypeptide was tested and found to have a molecular weight of 4133.72 and a purity of 92.13%. The polypeptide properties are detailed below. Figure 2 .
[0037] Table 1 Synthetic polypeptide sequences
[0038] Serial Number polypeptide name sequence SEQ ID NO:1 R58A YGRKKRRQRRRQIGYWNEQIAWRMRRGERIE SEQ ID NO:2 CCPs YGRKKRRQRRR
[0039] (2) R58A peptide is non-toxic to IPEC-J2 cells.
[0040] Normal porcine intestinal epithelial cells (IPEC-J2 cells) were treated with different concentrations of R58A peptide (1, 5, 10, 20, and 50 μg / mL) in both mock and blank wells for 24 h. 10 μL of CCK-8 dye was added to 100 μL of culture medium, and after 1 h of incubation, the OD450 value was measured using a microplate reader to calculate cell viability. The results showed no significant difference between the R58A peptide treatment and the mock well treatment, indicating that it was non-toxic to IPEC-J2 cells. Figure 3 ).
[0041] (3) PEDV N-R58A peptide can act as an antiviral effector to inhibit PEDV replication.
[0042] IPEC-J2 cells were pre-incubated with different concentrations of R58A peptide (1, 5, 10, 20, and 50 μg / mL) for 1 h, followed by PEDV infection. After 4 h of adsorption, 4 μg / mL trypsin was added for maintenance, along with the same amount of peptide as during pre-incubation. RNA and protein were harvested from the samples 24 h after infection. RNA extraction and probe assay revealed that the R58A mutant peptide significantly reduced the transcription level of the PEDV N gene, with the best inhibitory effect observed at concentrations of 1–10 μg / mL. Figure 4 However, it had no significant effect on the transcriptional level of the PEDV ORF1 gene. Western blot analysis was performed to detect the expression levels of PEDV S1 and PEDV N proteins. The results showed that the R58A mutant peptide significantly reduced the expression of PEDV N and PEDV S1 proteins. Figure 4 ).
[0043] Example 2: Application of PEDV N-R58A peptide in other susceptible cells
[0044] Following the procedure described in Example 1, African green monkey kidney cells (Vero cells) and porcine testicular cells (ST cells) were pre-incubated with 1, 5, and 10 μg / mL R58A peptide for 1 h, respectively. After PEDV infection with an MOI of 1 for 4 h, 4 μg / mL trypsin and the same amount of peptide as during pre-incubation were added to the culture medium. Cells were lysed 24 h after infection, and the expression of PEDV-N protein in the cells was detected. The results showed that the PEDV-N protein level in the R58A mutant peptide group in Vero cells gradually decreased in a dose-dependent manner. Figure 5 In ST cells, the expression of PEDV N protein was inhibited with increasing PEDV N-R58A peptide concentration, showing a dose-dependent trend. Figure 5 ).
[0045] Analysis and Conclusion:
[0046] Based on the results of Examples 1 and 2, it can be seen that the R58A polypeptide provided by this invention can interrupt the PEDV replication process, and therefore can be further used as an inhibitor targeting the PEDV viral replication stage, thereby suppressing the spread of PEDV. Furthermore, based on the non-toxic effects exhibited by this polypeptide on susceptible cells such as IPEC-J2, Vero, and ST, its application value as an active component of antiviral drugs is further verified.
[0047] Based on the results of multiple verifications by the applicant, it was confirmed that the peptide exhibits the best inhibitory effect on PEDV-N protein expression when used at a concentration of 1–10 μg / mL.
[0048] The scope of protection of this invention is not limited to the specific embodiments described above; it should also be understood that the terminology used in the embodiments of this invention is for describing specific embodiments and not for limiting the scope of protection of this invention. Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, based on the knowledge of those skilled in the art and the description of this invention, any prior art methods, equipment, and materials similar to or equivalent to those described, used, and materials in the embodiments of this invention can be used to implement this invention. Various modifications and variations can be made to this invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of this invention should be included within the scope of protection of this invention.
Claims
1. A polypeptide for inhibiting the replication of porcine epidemic diarrhea virus, characterized in that, This polypeptide is a transmembrane polypeptide that targets the replication phase of PEDV, with arginine at position 58 in the nucleocapsid N protein sequence of PEDV as the target site; the polypeptide is named R58A polypeptide, and its amino acid sequence is shown in SEQ ID NO:
1.
2. A method for inhibiting PEDV viral replication in vitro using the polypeptide of claim 1 for non-therapeutic purposes, characterized in that, The method involves pre-incubating isolated IPEC-J2, Vero, or ST cells with the polypeptide, then adding the same amount of polypeptide as during pre-incubation after PEDV infection, lysing the cells, harvesting the samples, and detecting the expression of PEDV-N protein in the cells.
3. The method according to claim 2, characterized in that, When performing peptide pre-incubation, the concentration of the peptide used is 1–10 μg / mL.
4. A pharmaceutical composition for inhibiting the replication of porcine epidemic diarrhea virus, characterized in that, The pharmaceutical composition comprises the polypeptide of claim 1, and a pharmaceutically acceptable carrier or adjuvant.
5. The use of the polypeptide composition of claim 4 in the preparation of a vaccine for the prevention of porcine epidemic diarrhea virus.
6. Use of the polypeptide composition of claim 4 in the preparation of a medicament for treating porcine epidemic diarrhea virus.
Citation Information
Patent Citations
Polypeptide for enhancing porcine epidemic diarrhea virus replication and application thereof
CN119080952A
